BIOMAT Database Logo BIOMAT Database Logo

Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. 2003

Estrella Gómez-Tortosa, and Isabel Gonzalo, and Samira Fanjul, and Maria José Sainz, and Susana Cantarero, and Carlos Cemillán, and Justo García Yébenes, and Teodoro del Ser
Department of Neurology, Fundación Jiménez Díaz, the Brain Bank for Neurological Research, Complutense University, Madrid, Spain. egomez@fjd.es

BACKGROUND Most patients with dementia with Lewy bodies (DLB) exhibit diffuse plaque-only pathology with rare neocortical neurofibrillary tangles (NFTs), as opposed to the widespread cortical neurofibrillary-tau involvement in Alzheimer disease (AD). Another pathological difference is the astrocytic and microglial inflammatory responses, including release of interleukins (ILs), around the neuritic plaques and NFTs in AD brains that are absent or much lower in DLB. We analyzed cerebrospinal fluid (CSF) markers that reflect the pathological differences between AD and DLB. OBJECTIVE To determine CSF concentrations of tau, beta-amyloid, IL-1beta, and IL-6 as potential diagnostic clues to distinguish between AD and DLB. METHODS We measured total tau, beta-amyloid1-42, IL-1beta, and IL-6 levels in CSF samples of 33 patients with probable AD without parkinsonism, 25 patients with all the core features of DLB, and 46 age-matched controls. RESULTS Patients with AD had significantly higher levels of tau protein than patients with DLB and controls (P<.001). The most efficient cutoff value provided 76% specificity to distinguish AD and DLB cases. Patients with AD and DLB had lower, but not significantly so, beta-amyloid levels than controls. The combination of tau and beta-amyloid levels provided the best sensitivity (84%) and specificity (79%) to differentiate AD vs controls but was worse than tau values alone in discriminating between AD and DLB. Beta-amyloid levels had the best correlation with disease progression in both AD and DLB (P =.01). There were no significant differences in IL-1beta levels among patients with AD, patients with DLB, and controls. Patients with AD and DLB showed slightly, but not significantly, higher IL-6 levels than controls. CONCLUSIONS The tau levels in CSF may contribute to the clinical distinction between AD and DLB. Beta-amyloid CSF levels are similar in both dementia disorders and reflect disease progression better than tau levels. Interleukin CSF concentrations do not distinguish between AD and DLB.

UI MeSH Term Description Entries
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D008297 Male Males
D009483 Neuropsychological Tests Tests designed to assess neurological function associated with certain behaviors. They are used in diagnosing brain dysfunction or damage and central nervous system disorders or injury. Aphasia Tests,Cognitive Test,Cognitive Testing,Cognitive Tests,Memory for Designs Test,Neuropsychological Testing,AX-CPT,Behavioral Assessment of Dysexecutive Syndrome,CANTAB,Cambridge Neuropsychological Test Automated Battery,Clock Test,Cognitive Function Scanner,Continuous Performance Task,Controlled Oral Word Association Test,Delis-Kaplan Executive Function System,Developmental Neuropsychological Assessment,Hooper Visual Organization Test,NEPSY,Neuropsychologic Tests,Neuropsychological Test,Paced Auditory Serial Addition Test,Repeatable Battery for the Assessment of Neuropsychological Status,Rey-Osterrieth Complex Figure,Symbol Digit Modalities Test,Test of Everyday Attention,Test, Neuropsychological,Tests, Neuropsychological,Tower of London Test,Neuropsychologic Test,Test, Cognitive,Testing, Cognitive,Testing, Neuropsychological,Tests, Cognitive
D003072 Cognition Disorders Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment. Overinclusion,Disorder, Cognition,Disorders, Cognition
D003463 Cues Signals for an action; that specific portion of a perceptual field or pattern of stimuli to which a subject has learned to respond. Cue
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D001253 Astrocytes A class of large neuroglial (macroglial) cells in the central nervous system - the largest and most numerous neuroglial cells in the brain and spinal cord. Astrocytes (from "star" cells) are irregularly shaped with many long processes, including those with "end feet" which form the glial (limiting) membrane and directly and indirectly contribute to the BLOOD-BRAIN BARRIER. They regulate the extracellular ionic and chemical environment, and "reactive astrocytes" (along with MICROGLIA) respond to injury. Astroglia,Astroglia Cells,Astroglial Cells,Astrocyte,Astroglia Cell,Astroglial Cell,Astroglias,Cell, Astroglia,Cell, Astroglial

Related Publications

Estrella Gómez-Tortosa, and Isabel Gonzalo, and Samira Fanjul, and Maria José Sainz, and Susana Cantarero, and Carlos Cemillán, and Justo García Yébenes, and Teodoro del Ser
Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
November 2008, Biological psychiatry,
Estrella Gómez-Tortosa, and Isabel Gonzalo, and Samira Fanjul, and Maria José Sainz, and Susana Cantarero, and Carlos Cemillán, and Justo García Yébenes, and Teodoro del Ser
Cerebrospinal fluid markers analysis in the differential diagnosis of dementia with Lewy bodies and Parkinson's disease dementia.
June 2020, European archives of psychiatry and clinical neuroscience,
Estrella Gómez-Tortosa, and Isabel Gonzalo, and Samira Fanjul, and Maria José Sainz, and Susana Cantarero, and Carlos Cemillán, and Justo García Yébenes, and Teodoro del Ser
Cerebrospinal fluid biomarkers for dementia with lewy bodies.
October 2010, International journal of Alzheimer's disease,
Estrella Gómez-Tortosa, and Isabel Gonzalo, and Samira Fanjul, and Maria José Sainz, and Susana Cantarero, and Carlos Cemillán, and Justo García Yébenes, and Teodoro del Ser
Classical Cerebrospinal Fluid Biomarkers in Dementia with Lewy Bodies.
April 2022, Medicina (Kaunas, Lithuania),
Estrella Gómez-Tortosa, and Isabel Gonzalo, and Samira Fanjul, and Maria José Sainz, and Susana Cantarero, and Carlos Cemillán, and Justo García Yébenes, and Teodoro del Ser
Clinical Manifestations of Early-Onset Dementia With Lewy Bodies Compared With Late-Onset Dementia With Lewy Bodies and Early-Onset Alzheimer Disease.
July 2022, JAMA neurology,
Estrella Gómez-Tortosa, and Isabel Gonzalo, and Samira Fanjul, and Maria José Sainz, and Susana Cantarero, and Carlos Cemillán, and Justo García Yébenes, and Teodoro del Ser
Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease.
January 2012, Alzheimer disease and associated disorders,
Estrella Gómez-Tortosa, and Isabel Gonzalo, and Samira Fanjul, and Maria José Sainz, and Susana Cantarero, and Carlos Cemillán, and Justo García Yébenes, and Teodoro del Ser
[Cerebrospinal fluid and plasma biomarkers for dementia with lewy bodies].
May 2012, Brain and nerve = Shinkei kenkyu no shinpo,
Estrella Gómez-Tortosa, and Isabel Gonzalo, and Samira Fanjul, and Maria José Sainz, and Susana Cantarero, and Carlos Cemillán, and Justo García Yébenes, and Teodoro del Ser
Dementia with Lewy bodies: cerebrospinal fluid suppresses neuronal network activity.
November 2017, Neuroreport,
Estrella Gómez-Tortosa, and Isabel Gonzalo, and Samira Fanjul, and Maria José Sainz, and Susana Cantarero, and Carlos Cemillán, and Justo García Yébenes, and Teodoro del Ser
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease.
January 2014, Alzheimer's research & therapy,
Estrella Gómez-Tortosa, and Isabel Gonzalo, and Samira Fanjul, and Maria José Sainz, and Susana Cantarero, and Carlos Cemillán, and Justo García Yébenes, and Teodoro del Ser
Low-abundant cerebrospinal fluid proteome alterations in dementia with Lewy bodies.
January 2013, Journal of Alzheimer's disease : JAD,
Copied contents to your clipboard!